Equillium, Inc.

NASDAQ:EQ

0.85 (USD) • At close September 18, 2024
Bedrijfsnaam Equillium, Inc.
Symbool EQ
Munteenheid USD
Prijs 0.85
Beurswaarde 30,110,740
Dividendpercentage 0%
52-weken bereik 0.45 - 3.25
Industrie Biotechnology
Sector Healthcare
CEO Mr. Bruce D. Steel C.F.A.
Website https://equilliumbio.com

An error occurred while fetching data.

Over Equillium, Inc.

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials

Vergelijkbare Aandelen

Fortress Biotech, Inc. logo

Fortress Biotech, Inc.

FBIO

1.92 USD

Celcuity Inc. logo

Celcuity Inc.

CELC

15.01 USD

Surrozen, Inc. logo

Surrozen, Inc.

SRZN

8.01 USD

Trevi Therapeutics, Inc. logo

Trevi Therapeutics, Inc.

TRVI

3.41 USD

Aptose Biosciences Inc. logo

Aptose Biosciences Inc.

APTO

0.408 USD

iCAD, Inc. logo

iCAD, Inc.

ICAD

1.63 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)